Medicure Reports Financial Results for Quarter Ended March 31, 2021

Rhea-AI Summary

Medicure reported its Q1 2021 results, showing net revenue of $4.9 million, up from $3.0 million in Q1 2020. The sales from AGGRASTAT® were $2.6 million, slightly down from $2.7 million year-over-year. Significant contributions came from Marley Drug, generating $2.1 million in revenue, alongside ZYPITAMAG® with $161,000. Adjusted EBITDA improved to $31,000 compared to a loss of $1.3 million in the previous year. The net loss reduced to $1.0 million or $0.10 per share from $1.5 million or $0.14 per share in Q1 2020.

Positive

• Total net revenue increased to $4.9 million from $3.0 million year-over-year.
• Adjusted EBITDA improved to $31,000 compared to negative $1.3 million in Q1 2020.
• Net loss decreased to $1.0 million from $1.5 million, indicating improved financial health.
• Marley Drug contributed $2.1 million in revenue, enhancing product diversification.

Negative

• AGGRASTAT® revenue declined slightly from $2.7 million to $2.6 million year-over-year.
• ZYPITAMAG® revenue decreased marginally from $163,000 to $161,000.

WINNIPEG, May 10, 2021 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today reported its results from operations for the quarter ended March 31, 2021. 

Quarter Ended March 31, 2021 Highlights:

• Recorded total net revenue of $4.9 million during the quarter ended March 31, 2021 compared to $3.0 million for the quarter ended March 31, 2020 and;
• Recorded total net revenue from the sale of AGGRASTAT^® of $2.6 million during the quarter ended March 31, 2021 compared to $2.7 million for the quarter ended March 31, 2020 and;
• Diversified product portfolio with revenues from the Marley Drug business of $2.1 million and ZYPITAMAG^® revenues of $161,000 during the quarter ended March 31, 2021 and;
• Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA¹) for the quarter ended March 31, 2021 was $31,000 compared to adjusted EBITDA of negative $1.3 million for the quarter ended March 31, 2020 and;
• Net loss for the quarter ended March 31, 2021 was $1.0 million compared to $1.5 million for the quarter ended March 31, 2020.

Financial Results

AGGRASTAT^® revenues were consistent when compared to the same period in the previous year. The Company continues to maintain the majority of patient market share in the GPI IIb/IIIa drug class.

ZYPITAMAG^® contributed $161,000 of revenue for the quarter ended March 31, 2021 compared to $163,000 for the quarter ended March 31, 2020. The Company continues to pursue innovative marketing strategies to grow the usage of the product.

The Marley Drug business, acquired on December 17, 2020, contributed $2.1 million of revenue to the Company for the quarter ended March 31, 2021. Marley provides excellent customer service, cost competitive medications, expedited direct to patient delivery, and is licensed in 49 states, Washington D.C. and Puerto Rico. Its advanced operating systems include automated pill dispensing, an extended supply generic drug program, and an effective customer communication system. Marley has been successful in marketing directly to customers, providing access to medications without the need for insurance, and building a nationwide customer base.

Adjusted EBITDA for the three months ended March 31, 2021 was $31,000 compared to negative $1.3 million for the quarter ended March 31, 2020. The improvement in adjusted EBITDA experienced in 2021 is the result of increased revenues, primarily from the acquisition of Marley Drug, partially offset by higher selling expenses primarily related to the operation of the Marley Drug business.

Net loss for the quarter ended March 31, 2021 was $1.0 million or $0.10 per share compared to net loss of $1.5 million or $0.14 per share for the quarter ended March 31, 2020. The main factors contributing to the decrease in the net loss recorded for the quarter ended March 31, 2021 were the increased revenues, partially offset by higher selling expenses as noted above.

At March 31, 2021, the Company had unrestricted cash totaling $2.9 million, compared to $2.7 million of unrestricted cash held as of December 31, 2020. The Company is in the process of obtaining debt financing from a commercial bank to replenish its cash balance following the Marley Drug acquisition in December 2020. Cash from operating activities for the quarter ended March 31, 2021 totaled $224,000 compared to cash used in operating activities of $822,000 for the quarter ended March 31, 2020.

All amounts referenced herein are in Canadian dollars unless otherwise noted.

Notes

(1)

The Company defines EBITDA as "earnings before interest, taxes, depreciation, amortization and other income or expense" and Adjusted EBITDA as "EBITDA adjusted for non–cash and non-recurring items". The terms "EBITDA" and "Adjusted EBITDA", as it relates to the three months ended March 31, 2021 and 2020 results prepared using IFRS, do not have any standardized meaning according to IFRS. It is therefore unlikely to be comparable to similar measures presented by other companies.

Conference Call Info:

Topic:  Medicure's Annual 2020 and Q1 2021 Results

Call date:  Tuesday, May 11, 2021

Time:  7:30 AM Central Time (8:30 AM Eastern Time)

Canada toll: 1 (416) 764-8659

North American toll-free:  1 (888) 664-6392

Passcode:  not required

Webcast:    This conference call will be webcast live over the internet and can be accessed from the Medicure investor relations page at the following link: http://www.medicure.com/investors   

You may request international country-specific access information by e-mailing the Company in advance. Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call. A recording of the call will be available following the event at the Company's website.

About Medicure Inc.
Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT^® (tirofiban hydrochloride) injection and ZYPITAMAG^® (pitavastatin) tablets in the United States, where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, Inc. ("Marley"), a pharmacy located in North Carolina that offers an Extended Supply mail order drug program serving 49 states, Washington D.C. and Puerto Rico. Marley is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. For more information visit www.marleydrug.com. To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email info@marleydrug.com. For more information on Medicure please visit www.medicure.com. For additional information about AGGRASTAT^®, refer to the full Prescribing Information. For additional information about ZYPITAMAG^®, refer to the full Prescribing Information.

To be added to Medicure's e-mail list, please visit:     
http://medicure.mediaroom.com/alerts

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information: Statements contained in this press release that are not statements of historical fact, including, without limitation, statements containing the words "believes", "may", "plans", "will", "estimates", "continues", "anticipates", "intends", "expects" and similar expressions, may constitute "forward-looking information" within the meaning of applicable Canadian and U.S. federal securities laws (such forward-looking information and forward-looking statements are hereinafter collectively referred to as "forward-looking statements"). Forward-looking statements, include estimates, analysis and opinions of management of the Company made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors which the Company believes to be relevant and reasonable in the circumstances. Inherent in forward-looking statements are known and unknown risks, uncertainties and other factors beyond the Company's ability to predict or control that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements, and as such, readers are cautioned not to place undue reliance on forward-looking statements. Such risk factors include, among others, the Company's future product revenues, expected results, including future revenue from P5P, the likelihood of receiving a PRV, expected future growth in revenues, stage of development, additional capital requirements, risks associated with the completion and timing of clinical trials and obtaining regulatory approval to market the Company's products, the ability to protect its intellectual property, dependence upon collaborative partners, changes in government regulation or regulatory approval processes, and rapid technological change in the industry. Such statements are based on a number of assumptions which may prove to be incorrect, including, but not limited to, assumptions about: general business and economic conditions; the impact of changes in Canadian-US dollar and other foreign exchange rates on the Company's revenues, costs and results; the timing of the receipt of regulatory and governmental approvals for the Company's research and development projects; the availability of financing for the Company's commercial operations and/or research and development projects, or the availability of financing on reasonable terms; results of current and future clinical trials; the uncertainties associated with the acceptance and demand for new products and market competition. The foregoing list of important factors and assumptions is not exhaustive. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements or the foregoing list of factors, other than as may be required by applicable legislation. Additional discussion regarding the risks and uncertainties relating to the Company and its business can be found in the Company's other filings with the applicable Canadian securities regulatory authorities or the US Securities and Exchange Commission, and in the "Risk Factors" section of its Form 20F for the year ended December 31, 2020.

AGGRASTAT^® (tirofiban hydrochloride) injection and ZYPITAMAG^® (pitavastatin) tablets are registered trademarks of Medicure International Inc.

Condensed Consolidated Interim Statements of Financial Position
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)

	March 31, 2021		December 31, 2020
Assets
Current assets:
Cash and cash equivalents	$	2,856	$	2,716
Restricted cash	1,010		1,394
Accounts receivable	4,674		5,253
Inventories	4,837		5,139
Prepaid expenses	1,185		1,174
Total current assets	14,562		15,676
Non–current assets:
Property and equipment	1,546		1,640
Intangible assets	12,634		13,596
Goodwill	2,949		2,986
Other assets	150		156
Total non–current assets	17,279		18,378
Total assets	$	31,841	$	34,054
Liabilities and Equity
Current liabilities:
Accounts payable and accrued liabilities	$	6,495	$	6,979
Current portion of royalty obligation	326		362
Current portion of acquisition payable	629		637
Holdback payable	1,504		1,876
Current portion of contingent consideration	1,962		1,925
Current income taxes payable	162		164
Current portion of lease obligation	365		367
Total current liabilities	11,443		12,310
Non–current liabilities
Royalty obligation	279		335
Acquisition payable	1,146		1,132
Contingent consideration	52		51
Lease obligation	1,006		1,080
Total non–current liabilities	2,483		2,598
Total liabilities	13,926		14,908
Equity:
Share capital	80,917		80,917
Contributed surplus	10,347		10,294
Accumulated other comprehensive income	(6,733)		(6,497)
Deficit	(66,616)		(65,568)
Total Equity	17,915		19,146
Total liabilities and equity	$	31,841	$	34,054

Condensed Consolidated Interim Statements of Net Loss and Comprehensive Income (Loss)
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)

For the three months ended March 31	2021		2020
Revenue, net	$	4,936	$	3,010
Cost of goods sold	1,927		1,542
Gross profit	3,009		1,468
Expenses
Selling	2,768		2,069
General and administrative	585		800
Research and development	581		858
	3,934		3,727
Finance (income) costs:
Finance expense, net	121		73
Foreign exchange loss (gain), net	2		(868)
	123		(795)
Net loss before income taxes	$	(1,048)	$	(1,464)
Income tax (expense) recovery	-		-
	-		-
Net loss	$	(1,048)	$	(1,464)
Other comprehensive (loss) income:
Item that may be reclassified to profit or loss
Exchange differences on translation of foreign subsidiaries	(236)		1,491
Other comprehensive (loss) income, net of tax	(236)		1,491
Comprehensive (loss) income	$	(1,284)	$	27
Loss per share
Basic	$	(0.10)	$	(0.14)
Diluted	$	(0.10)	$	(0.14)

Condensed Consolidated Interim Statements of Cash Flows
(expressed in thousands of Canadian dollars, except per share amounts)
(unaudited)

For the three months ended March 31	2021		2020
Cash (used in) provided by:
Operating activities:
Net loss for the period	$	(1,048)	$	(1,464)
Adjustments for:
Current income tax recovery	-		-
Amortization of property, plant and equipment	94		75
Amortization of intangible assets	800		608
Share–based compensation	53		77
Write-down of inventories	-		207
Finance expense (income), net	121		73
Unrealized foreign exchange loss	2		401
Change in the following:
Accounts receivable	595		516
Inventories	302		(1,899)
Prepaid expenses	(11)		(110)
Accounts payable and accrued liabilities	(578)		680
Interest (paid) received, net	(7)		14
Royalties paid	(99)		-
Cash flows from (used) in operating activities	224		(822)
Financing activities:
Repayment of lease liability	(84)		-
Cash flows used in financing activities	(84)		-
Foreign exchange gain (loss) on cash held in foreign currency	-		545
Decrease in cash and cash equivalents	140		(277)
Cash and cash equivalents, beginning of period	2,716		12,965
Cash and cash equivalents, end of period	$	2,856	$	12,688

 

View original content:http://www.prnewswire.com/news-releases/medicure-reports-financial-results-for-quarter-ended-march-31-2021-301287925.html

SOURCE Medicure Inc.

FAQ

What were Medicure's Q1 2021 revenue figures for stock symbol MCUJF?

Medicure reported total net revenue of $4.9 million for Q1 2021.

How did Medicure's adjusted EBITDA change in Q1 2021?

Medicure's adjusted EBITDA improved to $31,000 in Q1 2021, up from a negative $1.3 million in Q1 2020.

What was the net loss reported by Medicure for the first quarter of 2021?

Medicure reported a net loss of $1.0 million or $0.10 per share for Q1 2021.

What impact did Marley Drug have on Medicure's revenue in Q1 2021?

Marley Drug contributed $2.1 million to Medicure's revenue for Q1 2021.